In vivo testing of an agonistic anti-GITR mAb that induces cell surface clustering to augment signal transduction and a 2nd Gen bispecific anti-GITR/PD1 Ab derivative for improved anti-tumor activity
NATIONAL CANCER INSTITUTE
· United States · $2.68M USD
We use cookies to keep your session secure, remember your preferences, and analyse site traffic with Google Analytics.
By continuing to use GrantFunds you agree to our
Privacy Policy
and
Terms of Use.